Individual Patient Data Meta-Analysis evaluating Camostat Mesilate to Treat COVID-19 in Community Settings

Haley Hedlin, Els Tobback, Justin Lee, Yiwen Wang, Ilaria Dragoni, Daniel C. Anthony, Kevin Dhaliwal, John Norrie, Sarah Halford, Jose Gotes, Mariana Moctezuma, Antonio Olivas-Martinez, Chaitan Khosla, Upi Singh, Jesper Damsgaard Gunst, Alonso Valdez, David Kershenobich, David Boutboul, Ole S. Søgaard, Marie-Angélique De Scheerder, Manisha Desai, Julie Parsonnet Camostat Pooled Analysis Consortium
doi: https://doi.org/10.1101/2024.05.15.24307072

Article Information

doi 
https://doi.org/10.1101/2024.05.15.24307072
History 
  • May 17, 2024.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Haley Hedlin1,**,
  2. Els Tobback2,
  3. Justin Lee1,
  4. Yiwen Wang1,
  5. Ilaria Dragoni3,
  6. Daniel C. Anthony4,
  7. Kevin Dhaliwal5,
  8. John Norrie6,
  9. Sarah Halford3,
  10. Jose Gotes7,
  11. Mariana Moctezuma7,
  12. Antonio Olivas-Martinez7,
  13. Chaitan Khosla8,9,
  14. Upi Singh10,11,
  15. Jesper Damsgaard Gunst12,13,
  16. Alonso Valdez7,
  17. David Kershenobich7,
  18. David Boutboul14,
  19. Ole S. Søgaard12,13,
  20. Marie-Angélique De Scheerder2,
  21. Manisha Desai*,1,15,16,
  22. Julie Parsonnet*,10,15 and
  23. Camostat Pooled Analysis Consortium
  1. 1Quantitative Sciences Unit, Department of Medicine, Stanford University, California, United States of America
  2. 2Department of General Internal Medicine, Ghent University Hospital, Ghent, Belgium
  3. 3Cancer Research UK Centre for Drug Development, London, United Kingdom
  4. 4Department of Pharmacology, University of Oxford, Oxford, United Kingdom
  5. 5Centre for Inflammation Research, University of Edinburgh, United Kingdom
  6. 6Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, United Kingdom
  7. 7Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
  8. 8Sarafan ChEM-H and the Stanford Innovative Medicines Accelerator, Stanford University, California, United States of America
  9. 9Departments of Chemistry and Chemical Engineering, Stanford University, California, United States of America
  10. 10Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, California, United States of America
  11. 11Department of Microbiology and Immunology, Stanford University, California, United States of America
  12. 12Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark
  13. 13Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
  14. 14Hematology Department, Hopital Cochin, Université Paris Cité, Paris, France
  15. 15Department of Epidemiology and Population Health, Stanford University, California, United States of America
  16. 16Department of Biomedical Data Science, Stanford University, California, United States of America
  1. ↵** Corresponding author; email: hedlin{at}stanford.edu

  1. ↵* Authors contributed equally

Back to top
Posted May 17, 2024.
Download PDF
Data/Code
Email
Individual Patient Data Meta-Analysis evaluating Camostat Mesilate to Treat COVID-19 in Community Settings
Haley Hedlin, Els Tobback, Justin Lee, Yiwen Wang, Ilaria Dragoni, Daniel C. Anthony, Kevin Dhaliwal, John Norrie, Sarah Halford, Jose Gotes, Mariana Moctezuma, Antonio Olivas-Martinez, Chaitan Khosla, Upi Singh, Jesper Damsgaard Gunst, Alonso Valdez, David Kershenobich, David Boutboul, Ole S. Søgaard, Marie-Angélique De Scheerder, Manisha Desai, Julie Parsonnet
medRxiv 2024.05.15.24307072; doi: https://doi.org/10.1101/2024.05.15.24307072
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area